SEC Comment Letter for Opus Genetics, Inc. (IRD) (CIK 0001228627) (IRD) — Jul 19, 2018

Opus Genetics, Inc. (IRD) (CIK 0001228627)
Date: July 19, 2018 · CIK: 0001228627 · Accession: 0000000000-18-022160

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-34079

Date

July 19, 2018

Author

Not clearly detected

Form

UPLOAD

Company

Opus Genetics, Inc. (IRD) (CIK 0001228627)

Letter

July 19, 2018 Douglas J. Swirsky President and Chief Financial Officer Rexahn Pharmaceuticals, Inc. 15245 Shady Grove Road, Suite 455 Rockville, MD 20850 Re:Rexahn Pharmaceuticals, Inc. Preliminary Proxy Statement on Schedule 14A Filed July 9, 2018 File No. 001-34079 Dear Mr. Swirsky: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Division of Corporation Finance Office of Healthcare & Insurance cc: William I. Intner, Esq.

Show Raw Text

July 19, 2018
Douglas J. Swirsky
President and Chief Financial Officer
Rexahn Pharmaceuticals, Inc.
15245 Shady Grove Road, Suite 455
Rockville, MD 20850
Re:Rexahn Pharmaceuticals, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed July 9, 2018
File No. 001-34079
Dear Mr. Swirsky:
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Division of Corporation Finance
Office of Healthcare & Insurance
cc:       William I. Intner, Esq.

SecProbe.io